New Test Helps Spot Bladder Cancer
Quick Urine Test Helped Detect Bladder Cancer's Return
WebMD News Archive
Jan. 17, 2006 -- A new urine test helps identify bladder cancer recurrences,
with results available before a patient leaves their doctor's office.
So says a study in The Journal of the American Medical Association.
The researchers included H. Barton Grossman, MD, of the University of Texas
M.D. Anderson Cancer Center.
The test, called BladderChek, screens urine for high levels of a protein
called NMP22. Results are available within an hour, without extra lab work or
special training for medical staff.
The test enhances -- but doesn't replace -- other screening methods, the
'Good News for Patients'
Barry Stein, MD, worked on the study and commented on it in a news
"This is good news for patients," says Stein, a professor of urology at
Brown Medical School and surgeon-in-chief of urology at Rhode Island Hospital
in Providence, R.I.
"If you have been treated for bladder cancer and are being monitored for
recurrence, the accuracy of your diagnosis is extremely important," Stein
Stein says it's too soon to know if the BladderChek test should be used on
its own, replacing other screening methods.
"We need to do further research," he says. "But if a test is developed that
is effective as a standalone, that would be a real benefit."
Watching for Recurrence
More than half a million people in the U.S. have had bladder cancer, making
it the country's fifth most common cancer, write Grossman and colleagues.
The chances of getting bladder cancer more than once are high -- about 50%
to 90%, depending on the cancer's stage, grade, and original tumors, the
researchers note. With odds like that, rigorous, repeated screening is
recommended to check for recurrences.
The main test, called cystoscopy, uses a tiny scope to examine the inside of
the bladder and is considered the gold standard. Another test, called cytology,
checks urine for abnormal changes in intact bladder cells.
Cytology's lab work takes time and the test isn't always as sensitive as
doctors would like, especially with low-grade or early cancers, write the
researchers. They note that no single test is flawless, so more than one method
is usually used.